CHO Cells in Bioprocessing: Engineering, Applications, and Best Practices

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Chinese hamster ovary (CHO) cells are the predominant mammalian host system for industrial recombinant protein production, responsible for the manufacture of the majority of approved therapeutic monoclonal antibodies, cytokines, and fusion proteins. Their unique combination of robust growth in suspension culture, capacity for human-compatible post-translational modifications, and established regulatory track record has cemented their position as the industry workhorse. This reference provides a comprehensive overview of CHO cell biology, engineering strategies, cultivation practices, and quality considerations essential for scientists working in biopharmaceutical development and manufacturing.

Introduction to CHO Cells

CHO cells are immortalized epithelial cells derived from the ovary of the Chinese hamster (Cricetulus griseus). First isolated in 1957 by Theodore Puck, these cells were initially used for genetic and nutritional studies before their potential for recombinant protein expression was recognized in the 1980s. Today, CHO cells are the most widely used mammalian expression system in the biopharmaceutical industry, producing over 70% of all recombinant therapeutic proteins approved for clinical use.

History and Development of CHO Cell Lines

The original CHO cell line was established from an ovarian biopsy and subsequently adapted to grow in monolayer culture. Through chemical mutagenesis and selective pressure, several derivative lineages were generated, each with distinct genetic features. The most commercially significant derivatives include:

• CHO-K1: The parental line requiring proline for growth due to a defect in glutamine synthetase (GS) activity.
• CHO-S: A suspension-adapted variant of CHO-K1 selected for growth in serum-free media.
• CHO-DG44: A dihydrofolate reductase (DHFR)-deficient line created by chemical mutagenesis, enabling DHFR-based selection and gene amplification.
• CHO-DXB11: Another DHFR-deficient line with a single functional DHFR allele, used for methotrexate (MTX)-mediated amplification.

The development of DHFR-deficient lines in the 1980s was a pivotal advance. By transfecting cells with a vector containing both the gene of interest and the DHFR gene, researchers could select for stable integrants using MTX, a DHFR inhibitor. Stepwise increases in MTX concentration drove amplification of the integrated vector sequences, leading to higher transgene copy numbers and increased protein yields. This approach, combined with subsequent improvements in vector design and cell culture media, has increased volumetric productivity from milligram-per-liter levels in early processes to multi-gram-per-liter titers in modern fed-batch cultures.

Why CHO Cells Are the Industry Workhorse

Several factors explain the dominance of CHO cells in biopharmaceutical production. First, they grow to high densities in suspension culture using chemically defined, animal-component-free media, facilitating large-scale manufacturing in stirred-tank bioreactors. Second, CHO cells perform complex post-translational modifications, including N-linked and O-linked glycosylation, that are essential for the efficacy and safety of many therapeutic proteins. Third, they are relatively resistant to human viral pathogens, reducing the risk of contamination in downstream processing. Fourth, the extensive regulatory history of CHO-derived products means that approval pathways are well-established, and regulatory agencies have deep familiarity with the safety profile of these cells. Finally, CHO cells are amenable to genetic manipulation, allowing for cell line engineering to improve productivity, glycan profiles, and resistance to apoptosis.

Key Characteristics of CHO Cells

Understanding the intrinsic biological properties of CHO cells is essential for designing effective bioprocesses and troubleshooting production issues.

Growth Characteristics and Adaptability

CHO cells are adherent in their native state but can be adapted to grow in single-cell suspension, a critical requirement for industrial scale-up. Suspension-adapted cells are typically maintained in chemically defined media supplemented with growth factors, amino acids, vitamins, and trace elements. Under optimal conditions, CHO cells exhibit a doubling time of approximately 18–24 hours in exponential phase, reaching maximum viable cell densities of 10–20 × 10⁶ cells/mL in fed-batch culture and up to 50–100 × 10⁶ cells/mL in perfusion systems.

CHO cells demonstrate remarkable metabolic plasticity. They can utilize both glucose and glutamine as primary carbon and energy sources, although this often leads to the accumulation of lactate and ammonia, which inhibit cell growth and protein production. Metabolic engineering strategies, such as knockdown of lactate dehydrogenase A (LDHA) or overexpression of pyruvate carboxylase (PC), have been employed to redirect carbon flux away from lactate production. Additionally, CHO cells can be adapted to grow at temperatures ranging from 30°C to 39°C, and mild hypothermia (31–33°C) is commonly used during the production phase to slow growth and enhance specific productivity.

Post-Translational Modifications and Glycosylation

The ability to perform human-like post-translational modifications is the primary reason mammalian cells are preferred over microbial systems for complex therapeutic proteins. CHO cells carry out N-linked glycosylation, O-linked glycosylation, disulfide bond formation, and proper protein folding in the endoplasmic reticulum and Golgi apparatus.

N-linked glycosylation is the most critical modification for therapeutic proteins, as glycan structure influences pharmacokinetics, immunogenicity, and effector function. CHO cells produce glycan structures that are largely compatible with the human immune system, including complex-type glycans with core fucose, galactose, and sialic acid residues. However, notable differences exist between CHO and human glycosylation pathways. CHO cells lack the enzymes required to synthesize N-glycolylneuraminic acid (Neu5Gc) and galactose-α-1,3-galactose (α-Gal) epitopes, both of which are immunogenic in humans. This is a significant safety advantage of CHO cells over other mammalian hosts such as mouse myeloma (NS0) cells.

The glycosylation profile of a recombinant protein is influenced by multiple factors, including the specific CHO cell line, culture conditions, and the protein's amino acid sequence. Key quality attributes monitored during process development include:

• Glycan occupancy and site heterogeneity: The presence or absence of glycans at specific N-linked sites.
• Galactosylation: The extent of terminal galactose residues, which affects antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
• Sialylation: Terminal sialic acid content, which impacts serum half-life.
• Core fucosylation: The presence of fucose on the core GlcNAc, which reduces ADCC activity by decreasing antibody binding to FcγRIIIa receptors.

CHO Cell Line Development and Engineering

The generation of a stable, high-producing CHO cell line is a multi-step process that typically requires 6–12 months. The key stages include vector design, transfection, selection, screening, and clonal isolation.

Expression Vector Design and Promoters

The expression vector is the blueprint for recombinant protein production. A typical vector contains the gene of interest (GOI) under the control of a strong promoter, a selection marker, and often an amplification system. The choice of promoter significantly impacts expression levels.

The human cytomegalovirus (CMV) immediate-early promoter is the most widely used promoter for CHO cell expression due to its high transcriptional activity. However, CMV promoter activity can be silenced over time through DNA methylation, contributing to cell line instability. Alternatives include the Chinese hamster elongation factor-1 alpha (EF-1α) promoter, the human ubiquitin C (UBC) promoter, and the simian virus 40 (SV40) early promoter. The EF-1α promoter often provides more stable long-term expression than CMV in CHO cells.

For high-level expression, the vector typically includes:

• A Kozak consensus sequence (GCCACCATGG) upstream of the start codon to enhance translation initiation.
• An intron sequence downstream of the promoter to increase mRNA stability and nuclear export.
• A polyadenylation signal (e.g., bovine growth hormone or SV40 polyA) for proper mRNA processing.
• A signal peptide sequence (e.g., from human serum albumin or murine IgG kappa chain) to direct the protein to the secretory pathway.

Selection Systems and Gene Amplification

Two dominant selection systems are used for stable cell line generation in CHO cells: the DHFR/MTX system and the glutamine synthetase (GS) system.

DHFR/MTX system: In DHFR-deficient CHO cells (e.g., DG44 or DXB11), the vector carries a functional DHFR gene alongside the GOI. Transfected cells are selected in media lacking hypoxanthine and thymidine, which forces survival only in cells expressing DHFR. Subsequent exposure to increasing concentrations of MTX (typically 5–500 nM) drives amplification of the DHFR locus and flanking GOI sequences, increasing transgene copy number and protein expression. This system is well-established but requires multiple rounds of amplification and can lead to genomic instability.

GS system: The GS enzyme catalyzes the synthesis of glutamine from glutamate and ammonia. CHO-K1 cells express endogenous GS, so the system requires a GS inhibitor, methionine sulfoximine (MSX), to create selective pressure. Cells are transfected with a vector containing both the GOI and a GS gene, then cultured in glutamine-free media containing MSX (typically 25–50 µM). The GS system offers the advantage of a single selection step without the need for gene amplification, and it is compatible with suspension-adapted CHO-K1 cells.

CRISPR and Site-Specific Integration

Traditional random integration of transgenes can lead to position effects, where the surrounding chromatin environment influences expression levels and stability. The advent of CRISPR-Cas9 technology has enabled site-specific integration of transgenes into defined genomic "hot spots" that support high, stable expression.

Common target loci for site-specific integration in CHO cells include:

• COSMC: A gene encoding a chaperone required for O-glycosylation; knockout of this locus is well-tolerated and can simplify glycan profiles.
• HPRT: The hypoxanthine-guanine phosphoribosyltransferase gene, which is non-essential in culture but provides a selectable marker.
• ROSA26: A safe harbor locus that supports ubiquitous expression without disrupting essential genes.

CRISPR-mediated knock-in strategies involve co-transfection of a Cas9 expression plasmid, a single-guide RNA (sgRNA) targeting the desired locus, and a donor vector containing homology arms flanking the GOI and selection marker. Homology-directed repair (HDR) results in site-specific integration. While HDR efficiency in CHO cells is typically low (1–10% of transfected cells), enrichment strategies using selection markers and fluorescence-activated cell sorting (FACS) can isolate correctly targeted clones.

For a detailed overview of the steps involved in generating stable production cell lines, see Stable Cell Line Generation. The broader context of expression system selection is covered in Cell Line Development.

Cultivation and Scale-Up in Bioprocessing

The success of a CHO cell-based bioprocess depends on careful control of the culture environment, including media composition, feeding strategy, and bioreactor operating parameters.

Media Composition and Feeding Strategies

Modern CHO cell culture media are chemically defined, meaning every component is known and controlled. These media typically contain:

• Amino acids: All 20 standard amino acids, with glutamine (4–8 mM) or glutamate as a substitute in GS-based systems.
• Carbohydrates: Glucose (10–25 mM) as the primary energy source, sometimes supplemented with galactose or mannose.
• Vitamins and cofactors: Choline, folic acid, inositol, and B-vitamins.
• Lipids and precursors: Cholesterol, fatty acids, and ethanolamine for membrane synthesis.
• Trace elements: Iron, zinc, selenium, and copper, often in chelated forms.
• Growth factors: Insulin or insulin-like growth factor-1 (IGF-1) at 5–20 mg/L, and transferrin or iron chelators.
• Buffering agents: Sodium bicarbonate (2–4 g/L) in equilibrium with CO₂, and sometimes HEPES for bench-scale work.
• Antifoam agents: Poloxamer 188 (0.1–1 g/L) to prevent shear damage in stirred bioreactors.

Feeding strategies are designed to maintain nutrient concentrations above critical thresholds while minimizing toxic byproduct accumulation. A typical fed-batch process involves:

1. Inoculate the bioreactor at 0.2–0.5 × 10⁶ cells/mL.
2. Grow cells in batch mode for 2–3 days until glucose falls below 3 g/L.
3. Begin daily or every-other-day feeding with a concentrated nutrient solution containing glucose (400–600 g/L), amino acids, and vitamins.
4. Control glucose concentration between 2–6 g/L and glutamine between 2–4 mM.
5. Monitor and control lactate below 2–3 g/L; if lactate exceeds this, reduce glucose feed or switch to a slower-metabolized carbon source.
6. Shift temperature to 31–33°C at the onset of the production phase (typically day 3–5) to slow growth and increase specific productivity.
7. Harvest when viability drops below 70–80%, typically at day 12–18.

Batch, Fed-Batch, and Perfusion Modes

Three primary bioreactor operating modes are used for CHO cell culture:

Fed-batch is the dominant mode in commercial manufacturing due to its balance of productivity, simplicity, and regulatory familiarity. Perfusion is increasingly used for unstable products or when high volumetric productivity is required, such as in integrated continuous manufacturing processes.

Scale-Up Challenges and Solutions

Scaling CHO cell cultures from shake flasks (50–500 mL) to production bioreactors (1,000–20,000 L) presents several challenges:

• Oxygen transfer: As scale increases, the surface-area-to-volume ratio decreases, making oxygen delivery more difficult. Solutions include increasing agitation speed, sparging with oxygen-enriched air, and using higher oxygen partial pressures. The volumetric oxygen transfer coefficient (kLa) should be maintained above 10–20 h⁻¹.
• CO₂ stripping: At high cell densities, CO₂ accumulation can occur, leading to elevated dissolved CO₂ (pCO₂) and reduced pH. This is managed by increasing gas flow rates and using larger sparger holes to enhance CO₂ stripping.
• Shear stress: Agitation and sparging generate hydrodynamic forces that can damage cells. Poloxamer 188 (Pluronic F-68) at 0.5–1 g/L protects cells from shear damage. Impeller tip speed should be kept below 2–3 m/s.
• Mixing time: In large bioreactors, mixing times can exceed 60 seconds, leading to concentration gradients. This is addressed by optimizing impeller design and placement.
• Temperature control: Large vessels have lower surface-area-to-volume ratios, making heat removal more challenging. Cooling jackets and internal coils are used to maintain temperature at 36–37°C.

For practical guidance on maintaining healthy cultures during scale-up, refer to Animal Cell Culture and Cell Passaging.

Optimization of Recombinant Protein Production

Maximizing yield and product quality requires a combination of genetic engineering of the host cell and systematic process optimization.

Metabolic Engineering and Cell Engineering

Metabolic engineering aims to redirect cellular metabolism toward efficient recombinant protein production. Key strategies include:

• Lactate reduction: Knockdown or knockout of LDHA reduces lactate production, while overexpression of PC or malate dehydrogenase (MDH) can increase flux into the TCA cycle. This reduces lactate accumulation and improves cell viability.
• Apoptosis inhibition: Overexpression of anti-apoptotic genes such as Bcl-2, Bcl-xL, or the baculoviral IAP repeat-containing protein (XIAP) delays cell death in the late production phase, extending culture duration and increasing cumulative protein yield.
• Unfolded protein response (UPR) modulation: Overexpression of chaperones such as BiP (GRP78), protein disulfide isomerase (PDI), and the transcription factor XBP-1s can enhance protein folding capacity and secretion.
• Glycosylation engineering: Overexpression of β-1,4-galactosyltransferase (B4GALT1) increases galactosylation, while knockdown of α-1,6-fucosyltransferase (FUT8) produces afucosylated antibodies with enhanced ADCC activity. Co-expression of α-2,3-sialyltransferase (ST3GAL4) and CMP-sialic acid transporter can improve sialylation.
• Growth factor independence: Engineering autocrine growth factor production (e.g., IGF-1) can reduce dependence on media supplementation.

Process Optimization and Quality by Design

Quality by Design (QbD) is a systematic approach to process development that emphasizes understanding the relationship between process parameters and critical quality attributes (CQAs). Key elements include:

• Design of Experiments (DoE): Multivariate statistical methods (e.g., response surface methodology) are used to identify optimal conditions for temperature, pH, dissolved oxygen (DO), and feed composition.
• Critical process parameters (CPPs): Parameters that significantly affect CQAs, such as pH (typically 6.8–7.2), temperature (31–37°C), DO (20–50% of air saturation), and osmolality (280–400 mOsm/kg).
• Process analytical technology (PAT): Real-time monitoring of glucose, lactate, cell density, and metabolite concentrations using in-line or at-line sensors enables automated feedback control.
• Scale-down models: Small-scale (2–250 mL) systems that mimic production-scale conditions are used for high-throughput optimization.

Typical process parameters for a fed-batch CHO culture are: pH 7.0 ± 0.1, temperature 36.5°C (growth) and 32°C (production), DO 30% air saturation, and agitation at 100–200 rpm in a stirred-tank bioreactor.

Quality Control and Regulatory Considerations

The regulatory landscape for CHO-derived biopharmaceuticals is stringent, reflecting the complexity and safety requirements of products intended for human use.

Glycosylation and Product Heterogeneity

Glycosylation is a critical quality attribute that must be controlled within defined specifications. Product heterogeneity arises from variability in glycan structures, C-terminal lysine processing, N-terminal pyroglutamate formation, and oxidation of methionine residues. Key analytical methods include:

• Liquid chromatography-mass spectrometry (LC-MS) for intact protein mass analysis and glycan profiling.
• Hydrophilic interaction chromatography (HILIC) with fluorescence detection for released N-glycan analysis.
• Capillary electrophoresis with laser-induced fluorescence (CE-LIF) for glycan separation.
• Charge variant analysis using ion-exchange chromatography or isoelectric focusing.

Acceptance criteria for glycosylation are typically set based on clinical experience and may include limits for high-mannose species, afucosylated glycans, and sialic acid content.

Viral Safety and Contamination Testing

Viral safety is a paramount concern for mammalian cell-derived products. The regulatory framework requires a three-pronged approach:

1. Source control: Use of well-characterized cell banks tested for adventitious agents.
2. Testing: In-process and end-of-production testing for viruses using both in vitro and in vivo methods.
3. Viral clearance: Demonstration of the capacity of downstream purification steps to remove or inactivate viruses, typically requiring ≥6 log reduction for relevant and model viruses.

The ICH Q5A guideline provides a comprehensive framework for viral safety evaluation. Key testing includes:

• In vitro assays for a broad range of viruses using indicator cell lines.
• In vivo assays in mice, guinea pigs, and embryonated eggs.
• Species-specific assays for murine and hamster viruses.
• Retrovirus testing using transmission electron microscopy and infectivity assays (e.g., XC plaque assay for xenotropic murine leukemia virus).

Mycoplasma contamination is a particular concern in CHO cell culture. Detection methods include culture-based assays (per FDA 21 CFR 610.12), PCR-based methods, and the use of fluorescent DNA-binding dyes. Prevention relies on strict aseptic technique, antibiotic-free media (which can mask contamination), and routine testing of cell banks and culture media.

Regulatory Guidelines and ICH Standards

The International Council for Harmonisation (ICH) guidelines that are most relevant to CHO cell bioprocessing include:

• ICH Q5A: Viral safety evaluation of biotechnology products.
• ICH Q5B: Analysis of the expression construct in cells used for production of r-DNA derived protein products.
• ICH Q5C: Stability testing of biotechnological/biological products.
• ICH Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products.
• ICH Q6B: Specifications for biotechnological/biological products.
• ICH Q8: Pharmaceutical development (QbD principles).
• ICH Q11: Development and manufacture of drug substances.

These guidelines emphasize the importance of a well-characterized cell bank system, including a master cell bank (MCB) and working cell bank (WCB), with defined limits for passage number and genetic stability.

Common Pitfalls and Troubleshooting in CHO Cell Bioprocessing

Even experienced scientists encounter challenges in CHO cell bioprocessing. The following are the most common failure modes and their solutions.

Cell Line Instability and Genetic Drift

Symptom: Declining productivity or altered product quality over extended culture duration or increasing passage number.

Causes: Loss of transgene copies, promoter silencing through DNA methylation, and chromosomal rearrangements.

Solutions:

• Limit passage number; establish a WCB and use cells within a defined passage window (typically <30 passages from MCB).
• Use site-specific integration into stable genomic loci to reduce position effects.
• Include insulator elements (e.g., chicken β-globin HS4) or matrix attachment regions (MARs) in the expression vector.
• Monitor productivity and gene copy number regularly during scale-up.
• Consider using a ubiquitously acting chromatin opening element (UCOE) to prevent promoter silencing.

Low Productivity and Clonal Variation

Symptom: Inconsistent yields between clones or batches, or lower-than-expected specific productivity.

Causes: Clonal heterogeneity, poor vector design, suboptimal selection conditions, or metabolic limitations.

Solutions:

• Use FACS-based single-cell sorting to isolate high-producing clones.
• Screen a sufficient number of clones (typically 100–500) to identify stable high-producers.
• Optimize the expression vector: use a strong promoter, optimize codon usage for CHO cells, and include a signal peptide matched to the protein.
• Evaluate different selection marker systems; the GS system often provides more stable expression than DHFR/MTX.
• Use Calculate Cell Viability tools to accurately assess culture health during clone screening.

Contamination and Mycoplasma Risks

Symptom: Sudden drop in viability, altered metabolism, or visible turbidity in culture.

Causes: Bacterial or fungal contamination from poor aseptic technique, mycoplasma contamination from contaminated reagents or equipment, and cross-contamination between cell lines.

Solutions:

• Implement rigorous aseptic technique: use laminar flow hoods, sterile single-use plastics, and proper gowning.
• Test all new reagents, media, and sera for mycoplasma before use.
• Perform routine mycoplasma testing (monthly) using PCR or culture-based methods.
• Use antibiotic-free media for routine culture to avoid masking low-level contamination.
• Quarantine new cell lines and test them before introducing them into the main laboratory.
• If contamination occurs, discard the culture immediately and decontaminate the incubator and work surfaces with 70% ethanol or appropriate disinfectants.

Additional troubleshooting considerations include:

• Low cell viability after thawing: Ensure proper freezing media (10% DMSO in complete media), controlled-rate freezing (-1°C/min), and rapid thawing at 37°C.
• Aggregation or clumping: Reduce calcium and magnesium in media, add anti-clumping agents (e.g., dextran sulfate), or increase agitation.
• High lactate production: Reduce glucose feed concentration, use galactose as a co-substrate, or engineer cells to reduce LDHA expression.
• Poor transfection efficiency: Optimize DNA-to-transfection reagent ratio, use electroporation for suspension cells, or use lentiviral vectors for hard-to-transfect lines.

Summary and Best Practices

Key Takeaways for Industrial Scientists

1. Choose the right cell line: Select CHO-K1 (GS system) or CHO-DG44 (DHFR system) based on your product and process requirements. Consider suspension-adapted, serum-free lines for scale-up.

1. Design vectors for stability: Use strong, stable promoters (EF-1α over CMV for long-term expression), include insulators or UCOEs, and consider site-specific integration with CRISPR.

1. Screen rigorously: Isolate clones using FACS, screen a large number of clones, and evaluate stability over at least 30–40 generations before selecting a production clone.

1. Control the process: Maintain tight control of pH, temperature, DO, and nutrient concentrations. Use DoE to define the design space and PAT for real-time monitoring.

1. Monitor product quality: Characterize glycosylation, charge variants, and aggregates early and often. Establish specifications based on clinical relevance.

1. Plan for viral safety: Use well-characterized cell banks, test for adventitious agents, and demonstrate viral clearance capacity in downstream processing.

1. Document everything: Maintain detailed records of cell bank history, passage numbers, and process parameters to support regulatory submissions.

Future Directions in CHO Cell Engineering

The field of CHO cell engineering continues to evolve rapidly. Emerging approaches include:

• Genome-scale engineering: CRISPR-based screens to identify genes that enhance productivity, growth, or glycan quality.
• Synthetic biology: Design of synthetic promoters, genetic circuits, and inducible expression systems for precise control of protein production.
• Glycoengineering: Development of CHO lines with humanized glycosylation pathways, including the production of afucosylated antibodies with enhanced ADCC.
• Continuous manufacturing: Integration of perfusion bioreactors with continuous downstream processing for end-to-end continuous biomanufacturing.
• Cell-free systems: While Cell-free Protein Synthesis System technologies are advancing, they are unlikely to replace CHO cells for complex therapeutic proteins requiring authentic post-translational modifications.

The continued development of CHO cell platforms will be driven by the need for higher productivity, improved product quality, and reduced manufacturing costs. By understanding the fundamental biology of CHO cells and applying systematic engineering approaches, scientists can overcome current limitations and develop robust, efficient bioprocesses for the next generation of biopharmaceuticals.

Frequently Asked Questions

What are CHO cells?

CHO cells are immortalized epithelial cells derived from the ovary of the Chinese hamster (Cricetulus griseus). They were first isolated in 1957 and have since become the most widely used mammalian host system for producing recombinant therapeutic proteins, including monoclonal antibodies, cytokines, and fusion proteins.

Why are CHO cells used?

CHO cells are used because they combine several advantageous properties: they grow to high densities in suspension culture using chemically defined media, they perform human-compatible post-translational modifications (particularly N-linked glycosylation), they are relatively resistant to human viral pathogens, and they have a long regulatory history that facilitates approval of CHO-derived products.

What is a CHO cell diagram?

A CHO cell diagram typically illustrates the key structural features of the cell, including the nucleus, endoplasmic reticulum, Golgi apparatus, mitochondria, and plasma membrane. In a bioprocessing context, a diagram may also show the recombinant protein expression pathway, from gene transcription in the nucleus to translation on ribosomes, folding in the ER, and glycosylation in the Golgi before secretion.

How are CHO cells engineered?

CHO cells are engineered through a multi-step process: (1) design of an expression vector containing the gene of interest and a selection marker, (2) transfection of the vector into CHO cells using electroporation or lipid-based methods, (3) selection of stable integrants using antibiotics or metabolic selection (DHFR/MTX or GS/MSX), (4) screening of clones for productivity, and (5) optional gene amplification or site-specific integration using CRISPR-Cas9.

What are the advantages of CHO cells over other expression systems?

Compared to E. coli, CHO cells perform proper protein folding and glycosylation, which are essential for many therapeutic proteins. Compared to yeast, CHO cells produce glycan structures more similar to human glycans, without the high-mannose or yeast-specific modifications that can be immunogenic. Compared to other mammalian cells (e.g., HEK293, NS0), CHO cells grow better in suspension, are more amenable to serum-free adaptation, and have a more extensive regulatory history.

What are the common problems with CHO cells?

Common problems include cell line instability (declining productivity over time), low or inconsistent protein yields, clonal variation, lactate and ammonia accumulation, glycosylation heterogeneity, and contamination risks (particularly mycoplasma). These issues are addressed through careful cell line engineering, process optimization, and rigorous quality control.

How do you scale up CHO cell culture?

Scale-up involves adapting cells to suspension culture, expanding from shake flasks to small bioreactors (1–10 L), and then to production scale (100–20,000 L). Key considerations include maintaining oxygen transfer (kLa), controlling CO₂ stripping, managing shear stress with protective agents like Poloxamer 188, and ensuring uniform mixing. A stepwise scale-up approach with consistent process parameters (pH, temperature, DO) is essential for success.

Further Reading

• Xu WJ et al. Progress in fed-batch culture for recombinant protein production in CHO cells. Applied microbiology and biotechnology. 2023. PubMed 36648523
• Fischer S, Handrick R, Otte K. The art of CHO cell engineering: A comprehensive retrospect and future perspectives. Biotechnology advances. 2015. PubMed 26523782
• Zeh N et al. The new frontier in CHO cell line development: From random to targeted transgene integration technologies. Biotechnology advances. 2024. PubMed 38950872
• Fu Y et al. Improvement strategies for transient gene expression in mammalian cells. Applied microbiology and biotechnology. 2024. PubMed 39365308
• Tihanyi B, Nyitray L. Recent advances in CHO cell line development for recombinant protein production. Drug discovery today. Technologies. 2020. PubMed 34895638
• Ritacco FV, Wu Y, Khetan A. Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies. Biotechnology progress. 2018. PubMed 30290072

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks